




**ZENITH DRUGS LIMITED**  
(Formerly - Zenith Drugs Private Limited)

**CONTACT US:**

 [www.zenithdrugs.com](http://www.zenithdrugs.com)

 [info@zenithdrugs.com](mailto:info@zenithdrugs.com)

 +91 93291 45074      CIN: L24231MP2000PLC014465

 **Plant Add. - 72/5 & 72/1, 72/3, 74/1/1, 75/1/1 Muradpura (Orangpura),  
Dhar Road, Near Kalarla, INDORE, PIN-453001 (MP) INDIA**



---

**Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001**

---

Date: May 28, 2026

To,  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400051, Maharashtra, India.

**NSE Symbol: ZENITHDRUG; ISIN- INE0QWN01013**

**Subject: Intimation of Registration of Manufacturing Plant & Products in Afghanistan and Receipt of First Export Orders**

Regulation: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, in line with the Company's continuous efforts and strong commitment towards expanding international markets while ensuring complete regulatory compliance, high quality standards, and affordable medicines, **Zenith Drugs Limited** has achieved a significant milestone in its export business.

The Company has successfully completed the registration process of its manufacturing plant and products in the **Afghanistan market** and has received provisional approval for commencement of business operations in the said market.

Further, the Company has secured its **first export orders aggregating to approximately INR 2.50 Crores** from a well-established pharmaceutical distributor in Afghanistan for **17 products**.

This development marks a significant step in the Company's international expansion strategy and reflects the growing confidence in the Company's manufacturing quality, regulatory capabilities, and global business vision.

The Company remains committed to expanding its global footprint by entering new countries and regions through continuous development of innovative products, new markets, and advanced technologies, while delivering quality healthcare solutions worldwide with reliability, compliance, and affordability at the core of its operations.

This is for your information and record.

Thank you.

**For Zenith Drugs Limited**

**Sakshi Bhawsar**  
**Company Secretary & Compliance Officer**